KYMR Live signaler | Maksimer profitt med Getagraph.com

KJøP 114692 min ago

@ $36.93

Utstedt: 14 feb 2024 @ 21:32

Avkastning: 1.27%

Forrige signal: feb 14 - 15:30

Forrige signal: Selg

Avkastning: 3.50 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	529 366
Gjennomsnittsvolum	639 964
Markedsverdi	2.29B
EPS	$0 ( 2024-05-02 )
Neste inntjeningsdato	( $-0.730 ) 2024-06-18
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.84
ATR14	$0.0450 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Baker Bros. Advisors Lp	Buy	32 000	Non-Qualified Stock Option (right to buy)
2024-03-28	Baker Bros. Advisors Lp	Buy	0	Common Stock
2024-03-28	Baker Bros. Advisors Lp	Buy	0	Common Stock
2024-03-28	Baker Bros. Advisors Lp	Buy	7 379 066	Prefunded Warrants
2024-03-14	Booth Bruce	Sell	34 473	Common Stock

INSIDER POWER
44.21
Last 97 transactions
Buy: 2 823 290 \| Sell: 1 008 904

Volum Korrelasjon

Lang: 0.15 (neutral)

Kort: 0.37 (neutral)

Signal:(59.897) Neutral

Kymera Therapeutics, Inc. Korrelasjon

10 Mest positive korrelasjoner
MRUS	0.941
SLN	0.938
SWTX	0.937
YMAB	0.936
IMNM	0.935
TNYA	0.933
SRTS	0.93
EOLS	0.927
REYN	0.923
FWRG	0.922

10 Mest negative korrelasjoner
RTPY	-0.94
VALN	-0.934
RELL	-0.921
BFRI	-0.907
DSWL	-0.907
CNTY	-0.905
CRCT	-0.902
BSGM	-0.899
KVSB	-0.897
SVOK	-0.897

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Kymera Therapeutics, Inc. Korrelasjon - Valuta/Råvare

0.00
( neutral )

-0.17
( neutral )

0.00
( neutral )

0.16
( neutral )

-0.51
( weak negative )

-0.52
( weak negative )

Kymera Therapeutics, Inc. Økonomi

Annual	2023
Omsetning:	$78.59M
Bruttogevinst:	$75.03M (95.46 %)
EPS:	$-2.52

FY	2023
Omsetning:	$78.59M
Bruttogevinst:	$75.03M (95.46 %)
EPS:	$-2.52

FY	2022
Omsetning:	$46.83M
Bruttogevinst:	$43.85M (93.64 %)
EPS:	$-2.82

FY	2021
Omsetning:	$72.83M
Bruttogevinst:	$72.83M (100.00 %)
EPS:	$-1.976

Financial Reports:

No articles found.

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.